KESIMPTA 20 mg/.4mL
ofatumumab · INJECTION, SOLUTION · Novartis Pharmaceuticals Corporation
KESIMPTA is a injection, solution containing ofatumumab at 20 mg/.4mL, taken subcutaneous. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- KESIMPTA
- Generic Name
- ofatumumab
- NDC Code (Product)
0078-1007- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 20 mg/.4mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA125326
- Drug Class
- CD20-directed Cytolytic Antibody [EPC]
- Marketing Start
- 10/26/2009
Recall History
No Recall HistoryFrequently Asked Questions
What is KESIMPTA used for?
KESIMPTA contains ofatumumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is KESIMPTA a controlled substance?
KESIMPTA is not classified as a controlled substance by the DEA.
What is the generic name for KESIMPTA?
The generic name for KESIMPTA is ofatumumab. There are no other listed brand versions of ofatumumab.
What is the NDC code for KESIMPTA 20 mg/.4mL?
The NDC (National Drug Code) for KESIMPTA 20 mg/.4mL is 0078-1007, listed by Novartis Pharmaceuticals Corporation.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)